• Explore /
  • Poster
  • / Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

Abstract Video & Slides Poster

Authors

Andrew Coveler

Andrew L. Coveler

Seattle Cancer Care Alliance/University of Washington, Seattle, WA

Andrew L. Coveler , David Lawrence Bajor , Ashiq Masood , Emrullah Yilmaz , Anthony Frank Shields , Milind M. Javle , Ravi Kumar Paluri , Gina M. Vaccaro , Mark Zalupski , Juneko E. Grilley-Olson , Hedy L. Kindler , Michael W. Schmitt , Martin Gutierrez

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT02376699

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS4671)

DOI

10.1200/JCO.2020.38.15_suppl.TPS4671

Abstract #

TPS4671

Poster Bd #

279

Abstract Disclosures

Similar Posters

First Author: David Lawrence Bajor

First Author: Andrew L. Coveler

First Author: David Lawrence Bajor

First Author: Johanna C. Bendell